Tercica rhIGF-1 short stature study
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Tercica began a Phase IIIb study of its recombinant human insulin-like growth factor-1 (rhIGF-1) in children with short stature caused by primary IGF-1 deficiency Oct. 28. The two-year study, which "will be the basis of a future regulatory filing," will enroll 160 pre-pubertal children whose height and IGF-1 levels are more than two standard deviations below normal. Primary endpoint is change in height SD over one year. Tercica plans to file a separate rhIGF-1 NDA in "early 2005" for severe primary IGF deficiency, a subset of patients whose height and serum IGF-1 levels are more than three standard deviations below normal. Thirty-thousand children have primary IGFD in the U.S., of which 6,000 have the severe form, Tercica estimates...
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.